ProShare Advisors LLC Reduces Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)

ProShare Advisors LLC lowered its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 12.1% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 5,154 shares of the company’s stock after selling 711 shares during the quarter. ProShare Advisors LLC’s holdings in Krystal Biotech were worth $946,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in KRYS. Jamison Private Wealth Management Inc. bought a new stake in Krystal Biotech during the 2nd quarter valued at $28,000. GAMMA Investing LLC boosted its holdings in shares of Krystal Biotech by 160.3% during the second quarter. GAMMA Investing LLC now owns 151 shares of the company’s stock worth $28,000 after purchasing an additional 93 shares during the period. Key Financial Inc purchased a new stake in shares of Krystal Biotech during the second quarter worth about $28,000. Blue Trust Inc. grew its stake in shares of Krystal Biotech by 2,328.6% in the second quarter. Blue Trust Inc. now owns 170 shares of the company’s stock worth $30,000 after purchasing an additional 163 shares during the last quarter. Finally, Quest Partners LLC purchased a new position in Krystal Biotech during the 2nd quarter valued at about $71,000. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the sale, the insider now directly owns 1,500,882 shares in the company, valued at approximately $296,814,424.32. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 14.10% of the stock is owned by insiders.

Krystal Biotech Stock Down 0.7 %

Shares of KRYS opened at $177.14 on Friday. Krystal Biotech, Inc. has a 52 week low of $93.95 and a 52 week high of $219.34. The stock has a market cap of $5.06 billion, a P/E ratio of 94.73 and a beta of 0.82. The business’s 50 day moving average price is $192.47 and its 200-day moving average price is $179.64.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Monday, August 5th. The company reported $0.53 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.50 by $0.03. Krystal Biotech had a return on equity of 1.99% and a net margin of 63.73%. The firm had revenue of $70.28 million during the quarter, compared to analyst estimates of $65.27 million. During the same quarter in the previous year, the firm earned ($1.25) EPS. Krystal Biotech’s quarterly revenue was up 70283900.0% compared to the same quarter last year. On average, equities analysts anticipate that Krystal Biotech, Inc. will post 3.13 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Krystal Biotech in a research report on Thursday, August 29th. Stifel Nicolaus boosted their price objective on shares of Krystal Biotech from $204.00 to $220.00 and gave the company a “buy” rating in a research report on Wednesday, September 11th. Chardan Capital raised their target price on shares of Krystal Biotech from $153.00 to $208.00 and gave the stock a “buy” rating in a research report on Monday, August 5th. Evercore ISI boosted their price target on shares of Krystal Biotech from $201.00 to $206.00 and gave the company an “outperform” rating in a research report on Monday, August 12th. Finally, HC Wainwright raised their price objective on shares of Krystal Biotech from $200.00 to $221.00 and gave the stock a “buy” rating in a report on Wednesday, August 28th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $196.75.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).